Home » Public Health & Safety » Children's Special Health Services » Newborn Screening Programs » Metabolic (Bloodspot) Screening » Metabolic (Bloodspot) Screening Information

Metabolic (Bloodspot) Screening Information

Children's Special Health Services

Public Health Laboratory Newborn Screening
Metabolic (Bloodspot) Screening

Most babies are healthy when they are born. Montana tests all babies because a few babies look healthy but have rare health problems. If we find these problems early, we can help prevent serious outcomes like mental retardation or death.

  • A few drops (1/8 tsp) of blood are safely collected from the baby’s heel on a special card, usually 1 or 2 days after birth. The Montana Public Health Laboratory receives the blood cards, has the testing done, and reports the results.
  • Approximately 12,500 babies were born in Montana in 2008. Seventeen babies (1 in 735) were treated for a condition detected by the newborn bloodspot screen.
  • The newborn screen may need to be repeated if the bloodspot sample was not adequate to complete testing, or if the first test suggested a possible health problem.
  • Follow-up services for babies with conditions detected by newborn screening are provided under a contract administered by Montana’s Children’s Special Health Services (CSHS). This includes support for regional pediatric specialty clinics or Shodair Children's Hospital.
  • Montana screens for
    • Amino acid metabolism disorders, including Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria (HCY), Citrullinemia/ Arginosuccinic Acidemia (CIT/ASA) and Tyrosinemia Type I (TYR1). These disorders occur in 1 in 10,000 to less than 1 in 100,000 births.
    • Organic acidemia disorders, including 3-hydroxy-3-methylglutaryl-CoA lyase deficiency (HMG), 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC), β-ketothiolase deficiency (BKT), Glutaric acidemia type I (GA1), Isovaleric acidemia (IVA), Methylmalonic acidemia (MUT and CblA,B), Multiple carboxylase deficiency (MCD), Propionic acidemia (PROP). These disorders occur in about 1 in 50,000 births overall.
    • Fatty acid oxidation disorders, including Carnitine uptake defect (CUD), Medium-chain acyl-CoA dehydrogenase deficiency (MCAD), Long-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD), Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD), and Trifunctional protein deficiency (TFP). These disorders occur in about 1 in 10,000 births overall.
    • Congenital hypothyroidism (CH), which occurs in about 1 in 3000 births.
    • Congenital adrenal hyperplasia (CAH), which occurs in about 1 in 12,000 births.
    • Cystic fibrosis (CF), which occurs in about 1 in 2500 births to those of European ancestry.
    • Hemoglobin disorders, including Sickle cell anemia (HbSS), Hemoglobin SC disease (HbSC), and Hemoglobin S/β-thalassemia (HbS/βth). Sickle cell anemia occurs in about 1 in 400 births to those of African ancestry, and about 1 in 10,000 Montana births.
    • Galactosemia (GALT), which occurs in about 1 in 60,000 births.
    • Biotinidase deficiency (BIOT), which occurs in about 1 in 60,000 births.


Linda Beischel, Coordinator
Laboratory Services Bureau
(406) 444-0984